fingolimod hydrochloride has been researched along with Acute Lymphoid Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bendall, LJ; Bradstock, KF; Hewson, J; Wallington-Beddoe, CT | 1 |
| Byrd, JC; Chen, CS; Dalton, JT; Frissora, F; Jarjoura, D; Lehman, A; Liu, Q; Ma, Y; Muthusamy, N; Perrotti, D; Santhanam, R; Zhao, X | 1 |
2 other study(ies) available for fingolimod hydrochloride and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells.
Topics: Adolescent; Aged; Autophagy; Caspases; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Child, Preschool; Cytoprotection; Enzyme Activation; Female; Fingolimod Hydrochloride; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Propylene Glycols; Protein Phosphatase 2; Reactive Oxygen Species; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Young Adult | 2011 |
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
Topics: Animals; Apoptosis; B-Lymphocytes; Caspases; Cell Line; Cysteine Endopeptidases; Down-Regulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lysophospholipids; Mice; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Propylene Glycols; Protein Phosphatase 2; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sphingosine; Xenograft Model Antitumor Assays | 2008 |